Showing 4601-4610 of 9153 results for "".
- Golfers Face Higher Risk for Skin Cancerhttps://practicaldermatology.com/news/golfers-face-higher-risk-for-skin-cancer/2461902/New research from the University of South Australia shows that golfers have a higher risk of skin cancer when compared to the general population. Fully 27% of golfers – or one in four – had been diagnosed with skin cancer, as compared with 7% of the gener
- A Clinician's Guide to Alopecia: Diagnosis, Treatment, and Preventionhttps://practicaldermatology.com/news/a-clinicians-guide-to-alopecia-diagnosis-treatment-and-prevention/2461898/Hair loss, also known as alopecia, is a prevalent condition that affects people across every demographic.1 Unlike other skin issues that may remain unnoticed for extended periods, hair loss is often immediately apparent to the patient. Recently, alopecia has gained significant media at
- Reinforcement Learning Model May Boost AI Skin Cancer Diagnosis Accuracyhttps://practicaldermatology.com/news/reinforcement-learning-model-may-boost-ai-skin-cancer-diagnosis-accuracy/2461897/Artificial intelligence (AI) is already being used to diagnose skin cancer, but so far, it can’t keep pace with the complex decision-making of doctors in practice. Now, an international research team is developing a learning method in which greater accuracy in AI results can be a
- Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Developmenthttps://practicaldermatology.com/news/sirnaomics-appoints-dr-francois-lebel-as-senior-vice-president-for-preclinical-and-clinical-development/2461896/Dr. Francois Lebel, M.D is the new Senior Vice President for preclinical and clinical development at Sirnaomics Ltd. "With multiple drug candidates moving into clinical studies, including two clinical trials advancing to late-stage development, Sirnaomics is embarkin
- Practical Dermatology® Unveils New Cover Redesign for July 2023 Issuehttps://practicaldermatology.com/news/practical-dermatology-unveils-new-cover-redesign-for-july-2023-issue/2461895/Bryn Mawr Communications, publisher of Practical Dermatology®, has announced a captivating new cover redesign for the magazine, which will debut with their upcoming July issue. This visual update signals the first of many changes coming to the publication. "We are thrilled to unveil our s
- Research Closes in on the Genetic Factors Underlying HS Riskhttps://practicaldermatology.com/news/research-closes-in-on-the-genetic-factors-underlying-hs-risk/2461893/Researchers have identified genetic locations for increased risk of hidradenitis suppurativa (HS). “This discovery is highly relevant because these changes may effect nearby genes in a way that leads to improper development of hair follicles and predispose them to the rupture,&rdq
- Taylor Harris Named New CEO at Cuterahttps://practicaldermatology.com/news/taylor-harris-named-new-ceo-at-cutera/2461892/Taylor Harris has been appointed Chief Executive Officer for Cutera, Inc., effective August 7, 2023. Mr. Harris will succeed Sheila Hopkins, who has been serving as Interim Chief Executive Officer since April 2023. Mr. Harris and Ms. Hopkins will both continue serving as memb
- FDA Approves Verrica Pharmaceuticals’ YCANTH for Molluscum Contagiosumhttps://practicaldermatology.com/news/fda-approves-verrica-pharmaceuticals-ycanth-for-molluscum-contagiosum/2461882/The U.S. Food and Drug Administration (FDA) has given its nod to Verrica Pharmaceuticals Inc.’s YCANTH (cantharidin) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients aged two and older. "It's the only topical FDA-approved therapy
- First AD Patient Dosed in Lynk Pharmaceuticals' Phase Ib Clinical Study of Topical JAK Inhibitorhttps://practicaldermatology.com/news/first-ad-patient-dosed-in-lynk-pharmaceuticals-phase-ib-clinical-study-of-topical-jak-inhibitor/2461881/The first atopic dermatitis (AD) patient has been dosed in a Phase Ib clinical trial of LNK01004, Lynk Pharmaceuticals Co., Ltd. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNK01004 ointment in Chinese patient
- LRP Celebrates Acne Positivity with Two-Day 'Positivity Lab' Pop-Up Experience in NYChttps://practicaldermatology.com/news/lrp-celebrates-acne-positivity-with-two-day-positivity-lab-pop-up-experience-in-nyc/2461879/La Roche-Posay is hosting a consumer pop-up experience to help destigmatize acne. The pop-up will feature an immersive "Science of Skin" exhibit, a meditation lounge in partnership with obé Fitness, Doodle Bar with custom art done by local artists, and a Positivity Phot